Level Zero Health announced today that it raised $6.9 million in a pre-seed funding round to support its remote, continuous monitoring platform. Redalpine, a leading European venture capital firm, led the funding round. HAX (SOSV), Entrepreneur First and other industry experts also participated in the round.
Related: Berlin Heals raises over 7m CHF for studies of new less invasive approaches
San Francisco-based Level Zero develops remote, continuous hormone monitoring platforms using first-of-their-kind DNA-based sensors. Its technology offers an alternative to invasive blood draws, detecting hormone levels in interstitial fluid (much like a glucose sensor).
Level Zero combines biochemistry and nanotechnology in a sleek, minimally invasive, wearable patch. Like a CGM, it attaches to the user’s arm and delivers real-time measurements of stress and reproductive hormones. The company says it has already validated the technology in simulated samples across 98% of the human clinical range.
According to the company, its advancement could transform IVF, menopause and testosterone replacement therapy, among other areas of healthcare.
Level Zero plans to use its funds for R&D and team expansion as it looks to bring the product to market.
“Our innovative remote monitoring technology marks an enormous leap forward in hormone testing, and this funding will enable us to bring this revolutionary solution to market,” said Ula Rustamova, CEO of Level Zero Health. “This breakthrough in health technology has come about in a relatively short amount of time, but already we are seeing strong demand from customers who recognize the benefits of hormone monitoring not only because it allows patients to skip invasive and inconvenient lab tests, but also because it captures critical data inaccessible before.”
